SciSparc (NASDAQ: SPRC) surged 59.01% as quantum computing initiative redefines drug discovery.

SciSparc (NASDAQ: SPRC) surged 59.01% in trading on September 25, 2025, reaching an intraday high of $6.20 and marking its highest level since September 2025. The stock’s sharp ascent followed the company’s announcement of a strategic initiative to integrate quantum computing into 3D protein modeling, a move positioned to redefine drug discovery for central nervous system (CNS) disorders and rare diseases.

The initiative, approved by SciSparc’s board, aims to address limitations in classical computing methods by leveraging quantum algorithms to simulate protein dynamics with unprecedented precision. This approach targets two key challenges: predicting protein folding and modeling protein-ligand interactions, which are critical for identifying drug candidates. By accelerating these processes, the company seeks to reduce the time and cost of traditional drug development, particularly for its existing programs such as SCI-110 and SCI-210.

SciSparc emphasized partnerships with quantum computing and structural biology experts to develop proprietary tools and intellectual property. The formation of a new Israeli subsidiary underscores the company’s commitment to operationalizing the initiative, tapping into Israel’s expertise in quantum technology and biotech. Investors interpreted this as a sign of long-term strategic focus, bolstered by the company’s alignment of quantum advancements with its therapeutic areas of expertise.

Market sentiment shifted rapidly following the announcement. Retail and institutional investors alike expressed heightened confidence, with trading volume spiking to 58.21 million shares—far exceeding the stock’s average. The move reflects optimism about SciSparc’s potential to transition from a clinical-stage biotech to a leader in quantum-enabled drug discovery. Analysts noted the initiative’s technical differentiation, as quantum computing could mitigate risks associated with protein misfolding and late-stage drug failures, a persistent challenge in pharmaceutical R&D.

While the initiative remains in its early stages, SciSparc’s forward-looking vision has repositioned the company at the intersection of cutting-edge technology and biopharma innovation. By addressing technical bottlenecks in protein modeling, the firm aims to generate proprietary IP and expand its pipeline, offering a compelling case for transformative growth in the life sciences sector.